Equity Profile

VERA

Vera Therapeutics, Inc.

Health CareBiotechnology$3.0B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Vera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth will provide insights into the company's market traction and the success of its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

VERA Q2-2026 Earnings Preview

Context

Company Snapshot

Vera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious autoimmune diseases. Operating in the health care sector, Vera's work is critical as it aims to address unmet medical needs and improve patient outcomes through advanced treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-46.67%

Avg Stock Reaction

-2.15%

Last Quarter Recap

In Q1-2026, Vera reported an EPS of -$1.69, missing estimates by a significant margin. The stock reacted negatively, dropping 1.95% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Vera's upcoming earnings are cautious, especially given the company's recent history of missing EPS estimates. Investors are looking for signs of improvement in both earnings and revenue.

Bull Case

If Vera can demonstrate progress in its clinical trials and show improved financial metrics, it could signal a turnaround, attracting more investor interest.

Bear Case

Conversely, continued losses and lack of significant updates on product development could lead to further declines in stock price, as investors may lose confidence in the company's future prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of ongoing clinical trials?

Investors are keen to understand how these trials are progressing, as successful outcomes could significantly boost the company's valuation.

Will there be any guidance on expected revenue growth for the upcoming quarters?

Clear guidance on revenue expectations is crucial for assessing the company's financial health and growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Vera's clinical trials to yield positive results, which could lead to a significant turnaround in sentiment.

Supporting Evidence

The options market is pricing in a 41.6% move, indicating expectations for volatility that may not align with historical performance.

Vera's recent history of missing EPS estimates could lead to overly cautious sentiment, ignoring potential positive developments.

Key Risk

If clinical trial results exceed expectations, it could drastically shift market sentiment and lead to a revaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on whether Vera can show signs of financial recovery and clinical success, which are critical for its future.

Bull Confirmed If

Demonstrating a reduction in EPS losses to below -$1.50 would indicate improved operational efficiency.

Bear Confirmed If

If EPS losses exceed -$2.00, it would raise concerns about the company's financial sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±41.6%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±41.6% while VERA has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

50.5%

Calls (14K)P/C Ratio: 0.02Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.8%, with a raw directional average of -1.5% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vera beats expectations and raises guidance, history suggests the stock could see a positive reaction of around 3.5% on the first day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience minimal movement as investors digest the news.

Miss

If Vera misses expectations again, history suggests a potential drop of around 2.15% in the stock price.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any preliminary results.
2Management's outlook on revenue growth for the next quarter.
3Any changes in the company's strategic direction or focus areas.
4Insights into cost management and operational efficiency improvements.
5Responses to analyst questions regarding competitive positioning in the biotechnology space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Vera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth will provide insights into the company's market traction and the success of its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

VERA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-46.67%

Avg Stock Reaction

-2.15%

Last Quarter Recap

In Q1-2026, Vera reported an EPS of -$1.69, missing estimates by a significant margin. The stock reacted negatively, dropping 1.95% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Vera can demonstrate progress in its clinical trials and show improved financial metrics, it could signal a turnaround, attracting more investor interest.

Bear Case

Conversely, continued losses and lack of significant updates on product development could lead to further declines in stock price, as investors may lose confidence in the company's future prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of ongoing clinical trials?

Investors are keen to understand how these trials are progressing, as successful outcomes could significantly boost the company's valuation.

Will there be any guidance on expected revenue growth for the upcoming quarters?

Clear guidance on revenue expectations is crucial for assessing the company's financial health and growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Vera's clinical trials to yield positive results, which could lead to a significant turnaround in sentiment.

Supporting Evidence

The options market is pricing in a 41.6% move, indicating expectations for volatility that may not align with historical performance.

Vera's recent history of missing EPS estimates could lead to overly cautious sentiment, ignoring potential positive developments.

Key Risk

If clinical trial results exceed expectations, it could drastically shift market sentiment and lead to a revaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on whether Vera can show signs of financial recovery and clinical success, which are critical for its future.

Bull Confirmed If

Demonstrating a reduction in EPS losses to below -$1.50 would indicate improved operational efficiency.

Bear Confirmed If

If EPS losses exceed -$2.00, it would raise concerns about the company's financial sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±41.6%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±41.6% while VERA has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

50.5%

Calls (14K)P/C Ratio: 0.02Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vera beats expectations and raises guidance, history suggests the stock could see a positive reaction of around 3.5% on the first day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience minimal movement as investors digest the news.

Miss

If Vera misses expectations again, history suggests a potential drop of around 2.15% in the stock price.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any preliminary results.
2Management's outlook on revenue growth for the next quarter.
3Any changes in the company's strategic direction or focus areas.
4Insights into cost management and operational efficiency improvements.
5Responses to analyst questions regarding competitive positioning in the biotechnology space.